88 results on '"Görbe, Anikó"'
Search Results
2. Clinical Frailty Scale (CFS) indicated frailty is associated with increased in-hospital and 30-day mortality in COVID-19 patients: a systematic review and meta-analysis
- Author
-
Rottler, Máté, Ocskay, Klementina, Sipos, Zoltán, Görbe, Anikó, Virág, Marcell, Hegyi, Péter, Molnár, Tihamér, Erőss, Bálint, Leiner, Tamás, and Molnár, Zsolt
- Published
- 2022
- Full Text
- View/download PDF
3. Identification of New, Translatable ProtectomiRs against Myocardial Ischemia/Reperfusion Injury and Oxidative Stress: The Role of MMP/Biglycan Signaling Pathways.
- Author
-
Szabados, Tamara, Molnár, Arnold, Kenyeres, Éva, Gömöri, Kamilla, Pipis, Judit, Pósa, Bence, Makkos, András, Ágg, Bence, Giricz, Zoltán, Ferdinandy, Péter, Görbe, Anikó, and Bencsik, Péter
- Subjects
REPERFUSION injury ,MYOCARDIAL ischemia ,CELLULAR signal transduction ,MYOCARDIAL infarction ,LABORATORY rats ,MYOCARDIAL perfusion imaging ,OXIDATIVE stress ,IDENTIFICATION - Abstract
Introduction: Ischemic conditionings (ICon) were intensively investigated and several protective signaling pathways were identified. Previously, we have shown the role of matrix metalloproteinases (MMP) in myocardial ischemia/reperfusion injury (MIRI) and the cardioprotective role of biglycan (BGN), a small leucine-rich proteoglycan in vitro. Here, we hypothesized that cardiac MMP and BGN signaling are involved in the protective effects of ICon. Methods: A reverse target-microRNA prediction was performed by using the miRNAtarget™ 2.0 software to identify human microRNAs with a possible regulatory effect on MMP and BGN, such as on related genes. To validate the identified 1289 miRNAs in the predicted network, we compared them to two cardioprotective miRNA omics datasets derived from pig and rat models of MIRI in the presence of ICons. Results: Among the experimentally measured miRNAs, we found 100% sequence identity to human predicted regulatory miRNAs in the case of 37 porcine and 24 rat miRNAs. Upon further analysis, 42 miRNAs were identified as MIRI-associated miRNAs, from which 24 miRNAs were counter-regulated due to ICons. Conclusions: Our findings highlight 24 miRNAs that potentially regulate cardioprotective therapeutic targets associated with MMPs and BGN in a highly translatable porcine model of acute myocardial infarction. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. An Observational Study on the Pharmacokinetics of Oseltamivir in Lactating Influenza Patients.
- Author
-
Fodor, Eszter, Nagy, Regina N., Nógrádi, András, Toovey, Stephen, Kamal, Mohamed A., Vadász, Péter, Bencsik, Péter, Görbe, Anikó, and Ferdinandy, Péter
- Subjects
BREASTFEEDING ,OSELTAMIVIR ,INFLUENZA ,BREAST milk ,PUERPERAL disorders ,LACTATION - Abstract
Influenza infection may lead to serious complications in the postpartum period, therefore, oseltamivir treatment in these patients and their breastfed infants is of great importance. However, the pharmacokinetics of oseltamivir in postpartum lactating women with acute influenza infection, and the consequent infant exposure to oseltamivir are still unknown, and these data would help in assessing risk and the need for dose adjustment in breastfed infants. Six lactating women with influenza‐like symptoms, at a standard dose of 75 mg oral oseltamivir twice daily for 5 days, were recruited in this phase IV clinical study during the 2011/2012 H1N1 pandemic seasons. Breast milk/colostrum and venous blood samples were taken at multiple timepoints, maternal urine samples were obtained from total output within the 12‐hour observational period following the seventh dose of oseltamivir. Oseltamivir phosphate (OP) reached a maximum 69.5 ± 29.4 ng/mL concentration in breast milk, higher than that found in the plasma, and showed elimination within ~ 8 hours. Oseltamivir carboxylate (active metabolite of OP) showed a lower, nearly steady‐state concentration in breast milk during the observational period (maximum plasma concentration (Cmax) = 38.4 ± 12.9 ng/mL). Based on estimated daily milk consumption of exclusively breastfed infants, their calculated daily exposure is < 0.1% of the infant dose of oseltamivir for treatment of influenza as per marketing authorization. Here, we provide the first maternal breast milk pharmacokinetic data for oral multiple‐dose oseltamivir in lactating patients with influenza and showed that its concentration in the breast milk is not sufficient to reach a therapeutic dose for breastfed infants. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. l-Alpha-glycerylphosphorylcholine can be cytoprotective or cytotoxic in neonatal rat cardiac myocytes: a double-edged sword phenomenon
- Author
-
Tuboly, Eszter, Gáspár, Renáta, Ibor, Miguel Olias, Gömöri, Kamilla, Kiss, Bernadett, Strifler, Gerda, Hartmann, Petra, Ferdinandy, Péter, Bartekova, Monika, Boros, Mihály, and Görbe, Anikó
- Published
- 2019
- Full Text
- View/download PDF
6. Droplet Digital PCR Is a Novel Screening Method Identifying Potential Cardiac G-Protein-Coupled Receptors as Candidate Pharmacological Targets in a Rat Model of Pressure-Overload-Induced Cardiac Dysfunction.
- Author
-
Sayour, Nabil V., Tóth, Viktória É., Nagy, Regina N., Vörös, Imre, Gergely, Tamás G., Onódi, Zsófia, Nagy, Noémi, Bödör, Csaba, Váradi, Barnabás, Ruppert, Mihály, Radovits, Tamás, Bleckwedel, Federico, Zelarayán, Laura C., Pacher, Pal, Ágg, Bence, Görbe, Anikó, Ferdinandy, Péter, and Varga, Zoltán V.
- Subjects
HEART diseases ,ANIMAL disease models ,DRUG repositioning ,DRUG target ,RNA sequencing ,PROSTAGLANDIN receptors - Abstract
The identification of novel drug targets is needed to improve the outcomes of heart failure (HF). G-protein-coupled receptors (GPCRs) represent the largest family of targets for already approved drugs, thus providing an opportunity for drug repurposing. Here, we aimed (i) to investigate the differential expressions of 288 cardiac GPCRs via droplet digital PCR (ddPCR) and bulk RNA sequencing (RNAseq) in a rat model of left ventricular pressure-overload; (ii) to compare RNAseq findings with those of ddPCR; and (iii) to screen and test for novel, translatable GPCR drug targets in HF. Male Wistar rats subjected to transverse aortic constriction (TAC, n = 5) showed significant systolic dysfunction vs. sham operated animals (SHAM, n = 5) via echocardiography. In TAC vs. SHAM hearts, RNAseq identified 69, and ddPCR identified 27 significantly differentially expressed GPCR mRNAs, 8 of which were identified using both methods, thus showing a correlation between the two methods. Of these, Prostaglandin-F2α-receptor (Ptgfr) was further investigated and localized on cardiomyocytes and fibroblasts in murine hearts via RNA-Scope. Antagonizing Ptgfr via AL-8810 reverted angiotensin-II-induced cardiomyocyte hypertrophy in vitro. In conclusion, using ddPCR as a novel screening method, we were able to identify GPCR targets in HF. We also show that the antagonism of Ptgfr could be a novel target in HF by alleviating cardiomyocyte hypertrophy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients: A systematic review and meta‐analysis.
- Author
-
Kiss, Fruzsina, Pohóczky, Krisztina, Görbe, Anikó, Dembrovszky, Fanni, Kiss, Szabolcs, Hegyi, Péter, Szakó, Lajos, Tóth, Lilla, Ezer, Éva Somogyiné, Szalai, Eszter, and Helyes, Zsuzsanna
- Subjects
DISEASE progression ,META-analysis ,MEDICAL information storage & retrieval systems ,CONFIDENCE intervals ,EPIDERMAL growth factor receptors ,CANCER chemotherapy ,SYSTEMATIC reviews ,MORTALITY ,HEAD & neck cancer ,ANTINEOPLASTIC agents ,CANCER patients ,RESEARCH funding ,PROGRESSION-free survival ,MEDLINE ,ODDS ratio ,SQUAMOUS cell carcinoma ,OVERALL survival - Abstract
Head and neck squamous cell carcinoma (HNSCC) is among the common tumors associated with high mortality. The aim of our meta‐analysis was to determine how additional anti‐epidermal growth factor receptor (EGFR) therapy to standard chemotherapy affects the progression‐free (PFS) and overall survival (OS) of the patients, besides the most common side effects. We used CENTRAL, MEDLINE, and Embase databases until October 26, 2020, and included 13 eligible randomized controlled trials in our systematic research. The pooled hazard ratios (HR) for the main outcomes from the original data were estimated and for the other dichotomous outcomes, odds ratios (ORs) with their 95% confidence intervals (CI) were calculated. Addition of EGFR inhibitors to conventional chemotherapy significantly decreased the death and disease progression (for PFS HR: 0.68, 95% CI: 0.55–0.81, I2 = 65.5%, p = 0.005) and mortality (for OS HR: 0.83, 95% CI: 0.72–0.94, I2 = 42.3%, p = 0.076). In the EGFR inhibitor group, we revealed an increased chance of the over Grade 3 skin rashes (OR: 4.86; 95% CI: 1.52–15.49, I2 = 2.3%, p = 0.407), and all Grade skin rashes (OR: 18.32, 95% CI: 8.07–41.60, I2 = 56.6%, p = 0.032). Despite their unwanted dermatological side effects, the addition of EGFR inhibitors is recommended to be included in advanced HNSCC therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Autophagosome formation is required for cardioprotection by chloramphenicol
- Author
-
Giricz, Zoltán, Varga, Zoltán V., Koncsos, Gábor, Nagy, Csilla Terézia, Görbe, Anikó, Mentzer, Robert M., Jr, Gottlieb, Roberta A., and Ferdinandy, Péter
- Published
- 2017
- Full Text
- View/download PDF
9. Effects of Bempedoic Acid in Acute Myocardial Infarction in Rats: No Cardioprotection and No Hidden Cardiotoxicity.
- Author
-
Gergely, Tamás G., Brenner, Gábor B., Nagy, Regina N., Sayour, Nabil V., Makkos, András, Kovácsházi, Csenger, Tian, Huimin, Schulz, Rainer, Giricz, Zoltán, Görbe, Anikó, and Ferdinandy, Péter
- Subjects
REPERFUSION ,CARDIOTOXICITY ,ANTILIPEMIC agents ,ISCHEMIC preconditioning ,ARRHYTHMIA ,RATS ,LABORATORY rats ,MYOCARDIAL infarction - Abstract
Lipid-lowering drugs have been shown to have cardioprotective effects but may have hidden cardiotoxic properties. Therefore, here we aimed to investigate if chronic treatment with the novel lipid-lowering drug bempedoic acid (BA) exerts hidden cardiotoxic and/or cardioprotective effects in a rat model of acute myocardial infarction (AMI). Wistar rats were orally treated with BA or its vehicle for 28 days, anesthetized and randomized to three different groups (vehicle + ischemia/reperfusion (I/R), BA + I/R, and positive control vehicle + ischemic preconditioning (IPC)) and subjected to cardiac 30 min ischemia and 120 min reperfusion. IPC was performed by 3 × 5 min I/R cycles before ischemia. Myocardial function, area at risk, infarct size and arrhythmias were analyzed. Chronic BA pretreatment did not influence cardiac function or infarct size as compared to the vehicle group, while the positive control IPC significantly reduced the infarct size. The incidence of reperfusion-induced arrhythmias was significantly reduced by BA and IPC. This is the first demonstration that BA treatment does not show cardioprotective effect although moderately reduces the incidence of reperfusion-induced arrhythmias. Furthermore, BA does not show hidden cardiotoxic effect in rats with AMI, showing its safety in the ischemic/reperfused heart. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Altered Cellular Protein Quality Control System Modulates Cardiomyocyte Function in Volume Overload-Induced Hypertrophy.
- Author
-
Gömöri, Kamilla, Herwig, Melissa, Hassoun, Roua, Budde, Heidi, Mostafi, Nusratul, Delalat, Simin, Modi, Suvasini, Begovic, Merima, Szabados, Tamara, Pipis, Judit, Farkas-Morvay, Nikolett, Leprán, István, Kovács, Árpád, Mügge, Andreas, Ferdinandy, Péter, Görbe, Anikó, Bencsik, Péter, and Hamdani, Nazha
- Subjects
HEAT shock proteins ,QUALITY control ,CONNECTIN ,HYPERTROPHY ,OXIDATIVE stress ,PROTEINS ,METABOLIC disorders - Abstract
Volume-induced hypertrophy is one of the risk factors for cardiac morbidity and mortality. In addition, mechanical and metabolic dysfunction, aging, and cellular redox balance are also contributing factors to the disease progression. In this study, we used volume overload (VO), which was induced by an aortocaval fistula in 2-month-old male Wistar rats, and sham-operated animals served as control. Functional parameters were measured by transthoracic echocardiography at termination 4- or 8-months after VO. The animals showed hypertrophic remodeling that was accompanied by mechanical dysfunction and increased cardiomyocyte stiffness. These alterations were reversible upon treatment with glutathione. Cardiomyocyte dysfunction was associated with elevated oxidative stress markers with unchanged inflammatory signaling pathways. In addition, we observed altered phosphorylation status of small heat shock proteins 27 and 70 and diminished protease expression caspases 3 compared to the matched control group, indicating an impaired protein quality control system. Such alterations might be attributed to the increased oxidative stress as anticipated from the enhanced titin oxidation, ubiquitination, and the elevation in oxidative stress markers. Our study showed an early pathological response to VO, which manifests in cardiomyocyte mechanical dysfunction and dysregulated signaling pathways associated with enhanced oxidative stress and an impaired protein quality control system. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection
- Author
-
Schulz, Rainer, Maximilian Görge, Philipp, Görbe, Anikó, Ferdinandy, Péter, Lampe, Paul D., and Leybaert, Luc
- Published
- 2015
- Full Text
- View/download PDF
12. Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo.
- Author
-
Weber, Bennet Y., Brenner, Gábor B., Kiss, Bernadett, Gergely, Tamás G., Sayour, Nabil V., Tian, Huimin, Makkos, András, Görbe, Anikó, Ferdinandy, Péter, and Giricz, Zoltán
- Subjects
MYOCARDIAL reperfusion ,ROSIGLITAZONE ,CARDIOTOXICITY ,REPERFUSION ,ISCHEMIC preconditioning ,ARRHYTHMIA ,ISCHEMIA - Abstract
Clinical observations are highly inconsistent with the use of the antidiabetic rosiglitazone regarding its associated increased risk of myocardial infarction. This may be due to its hidden cardiotoxic properties that have only become evident during post-marketing studies. Therefore, we aimed to investigate the hidden cardiotoxicity of rosiglitazone in ischemia/reperfusion (I/R) injury models. Rats were treated orally with either 0.8 mg/kg/day rosiglitazone or vehicle for 28 days and subjected to I/R with or without cardioprotective ischemic preconditioning (IPC). Rosiglitazone did not affect mortality, arrhythmia score, or infarct size during I/R. However, rosiglitazone abolished the antiarrhythmic effects of IPC. To investigate the direct effect of rosiglitazone on cardiomyocytes, we utilized adult rat cardiomyocytes (ARCMs), AC16, and differentiated AC16 (diffAC16) human cardiac cell lines. These were subjected to simulated I/R in the presence of rosiglitazone. Rosiglitazone improved cell survival of ARCMs at 0.3 μM. At 0.1 and 0.3 μM, rosiglitazone improved cell survival of AC16s but not that of diffAC16s. This is the first demonstration that chronic administration of rosiglitazone does not result in major hidden cardiotoxic effects in myocardial I/R injury models. However, the inhibition of the antiarrhythmic effects of IPC may have some clinical relevance that needs to be further explored. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Ca2+/calmodulin‐dependent protein kinase II and protein kinase G oxidation contributes to impaired sarcomeric proteins in hypertrophy model.
- Author
-
Gömöri, Kamilla, Herwig, Melissa, Budde, Heidi, Hassoun, Roua, Mostafi, Nusratul, Zhazykbayeva, Saltanat, Sieme, Marcel, Modi, Suvasini, Szabados, Tamara, Pipis, Judit, Farkas‐Morvay, Nikolett, Leprán, István, Ágoston, Gergely, Baczkó, István, Kovács, Árpád, Mügge, Andreas, Ferdinandy, Péter, Görbe, Anikó, Bencsik, Péter, and Hamdani, Nazha
- Subjects
CGMP-dependent protein kinase ,CONNECTIN ,PROTEIN kinases ,MUSCULAR hypertrophy ,PROTEIN models ,CARRIER proteins ,CELLULAR signal transduction - Abstract
Aims: Volume overload (VO) induced hypertrophy is one of the hallmarks to the development of heart diseases. Understanding the compensatory mechanisms involved in this process might help preventing the disease progression. Methods and results: Therefore, the present study used 2 months old Wistar rats, which underwent an aortocaval fistula to develop VO‐induced hypertrophy. The animals were subdivided into four different groups, two sham operated animals served as age‐matched controls and two groups with aortocaval fistula. Echocardiography was performed prior termination after 4‐ and 8‐month. Functional and molecular changes of several sarcomeric proteins and their signalling pathways involved in the regulation and modulation of cardiomyocyte function were investigated. Results: The model was characterized with preserved ejection fraction in all groups and with elevated heart/body weight ratio, left/right ventricular and atrial weight at 4‐ and 8‐month, which indicates VO‐induced hypertrophy. In addition, 8‐months groups showed increased left ventricular internal diameter during diastole, RV internal diameter, stroke volume and velocity‐time index compared with their age‐matched controls. These changes were accompanied by increased Ca2+ sensitivity and titin‐based cardiomyocyte stiffness in 8‐month VO rats compared with other groups. The altered cardiomyocyte mechanics was associated with phosphorylation deficit of sarcomeric proteins cardiac troponin I, myosin binding protein C and titin, also accompanied with impaired signalling pathways involved in phosphorylation of these sarcomeric proteins in 8‐month VO rats compared with age‐matched control group. Impaired protein phosphorylation status and dysregulated signalling pathways were associated with significant alterations in the oxidative status of both kinases CaMKII and PKG explaining by this the elevated Ca2+ sensitivity and titin‐based cardiomyocyte stiffness and perhaps the development of hypertrophy. Conclusions: Our findings showed VO‐induced cardiomyocyte dysfunction via deranged phosphorylation of myofilament proteins and signalling pathways due to increased oxidative state of CaMKII and PKG and this might contribute to the development of hypertrophy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Cardioprotection by Farnesol: Role of the Mevalonate Pathway
- Author
-
Szűcs, Gergő, Murlasits, Zsolt, Török, Szilvia, Kocsis, Gabriella F., Pálóczi, János, Görbe, Anikó, Csont, Tamás, Csonka, Csaba, and Ferdinandy, Péter
- Published
- 2013
- Full Text
- View/download PDF
15. Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective
- Author
-
Bencsik, Péter, Pálóczi, János, Kocsis, Gabriella F., Pipis, Judit, Belecz, István, Varga, Zoltán V., Csonka, Csaba, Görbe, Anikó, Csont, Tamás, and Ferdinandy, Péter
- Published
- 2014
- Full Text
- View/download PDF
16. Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone.
- Author
-
Vörös, Imre, Onódi, Zsófia, Tóth, Viktória Éva, Gergely, Tamás G., Sághy, Éva, Görbe, Anikó, Kemény, Ágnes, Leszek, Przemyslaw, Helyes, Zsuzsanna, Ferdinandy, Péter, and Varga, Zoltán V.
- Subjects
NEUROPEPTIDES ,HEART failure ,CARDIOTOXICITY ,NEUROPEPTIDE Y ,SUBSTANCE P ,HEART failure patients - Abstract
Dipeptidyl-peptidase-4 (DPP4) inhibitors are novel medicines for diabetes. The SAVOR-TIMI-53 clinical trial revealed increased heart-failure-associated hospitalization in saxagliptin-treated patients. Although this side effect could limit therapeutic use, the mechanism of this potential cardiotoxicity is unclear. We aimed to establish a cellular platform to investigate DPP4 inhibition and the role of its neuropeptide substrates substance P (SP) and neuropeptide Y (NPY), and to determine the expression of DDP4 and its neuropeptide substrates in the human heart. Western blot, radio-, enzyme-linked immuno-, and RNA scope assays were performed to investigate the expression of DPP4 and its substrates in human hearts. Calcein-based viability measurements and scratch assays were used to test the potential toxicity of DPP4 inhibitors. Cardiac expression of DPP4 and NPY decreased in heart failure patients. In human hearts, DPP4 mRNA is detectable mainly in cardiomyocytes and endothelium. Treatment with DPP4 inhibitors alone/in combination with neuropeptides did not affect viability but in scratch assays neuropeptides decreased, while saxagliptin co-administration increased fibroblast migration in isolated neonatal rat cardiomyocyte-fibroblast co-culture. Decreased DPP4 activity takes part in the pathophysiology of end-stage heart failure. DPP4 compensates against the elevated sympathetic activity and altered neuropeptide tone. Its inhibition decreases this adaptive mechanism, thereby exacerbating myocardial damage. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Infection Is Associated With Carotid Intima and Media Thickening: A Systematic Review and Meta-Analysis.
- Author
-
Simon, Orsolya Anna, Görbe, Anikó, Hegyi, Péter, Szakó, Lajos, Oštarijaš, Eduard, Dembrovszky, Fanni, Kiss, Szabolcs, Czopf, László, Erőss, Bálint, and Szabó, Imre
- Published
- 2022
- Full Text
- View/download PDF
18. Expression of sarcoplasmic/endoplasmic reticulum Ca2+ ATPases in the rat extensor digitorum longus (EDL) muscle regenerating from notexin-inducednecrosis
- Author
-
Mendler, Luca, Szakonyi, Gerda, Zádor, Ernô, Görbe, Anikó, Dux, László, and Wuytack, Frank
- Published
- 1998
- Full Text
- View/download PDF
19. AIM2-driven inflammasome activation in heart failure.
- Author
-
Onódi, Zsófia, Ruppert, Mihály, Kucsera, Dániel, Sayour, Alex Ali, Tóth, Viktória E, Koncsos, Gábor, Novák, Julianna, Brenner, Gábor B, Makkos, András, Baranyai, Tamás, Giricz, Zoltán, Görbe, Anikó, Leszek, Przemyslaw, Gyöngyösi, Mariann, Horváth, Iván G, Schulz, Rainer, Merkely, Béla, Ferdinandy, Péter, Radovits, Tamás, and Varga, Zoltán V
- Subjects
HEART failure ,INFLAMMASOMES ,DRUG target ,NLRP3 protein ,DILATED cardiomyopathy - Abstract
Aims Interleukin-1β (IL-1β) is an important pathogenic factor in cardiovascular diseases including chronic heart failure (HF). The CANTOS trial highlighted that inflammasomes as primary sources of IL-1 β are promising new therapeutic targets in cardiovascular diseases. Therefore, we aimed to assess inflammasome activation in failing hearts to identify activation patterns of inflammasome subtypes as sources of IL-1β. Methods and results Out of the four major inflammasome sensors tested, expression of the inflammasome protein absent in melanoma 2 (AIM2) and NLR family CARD domain-containing protein 4 (NLRC4) increased in human HF regardless of the aetiology (ischaemic or dilated cardiomyopathy), while the NLRP1/NALP1 and NLRP3 (NLR family, pyrin domain containing 1 and 3) inflammasome showed no change in HF samples. AIM2 expression was primarily detected in monocytes/macrophages of failing hearts. Translational animal models of HF (pressure or volume overload, and permanent coronary artery ligation in rat, as well as ischaemia/reperfusion-induced HF in pigs) demonstrated activation pattern of AIM2 similar to that of observed in end-stages of human HF. In vitro AIM2 inflammasome activation in human Tohoku Hospital Pediatrics-1 (THP-1) monocytic cells and human AC16 cells was significantly reduced by pharmacological blockade of pannexin-1 channels by the clinically used uricosuric drug probenecid. Probenecid was also able to reduce pressure overload-induced mortality and restore indices of disease severity in a rat chronic HF model in vivo. Conclusions This is the first report showing that AIM2 and NLRC4 inflammasome activation contribute to chronic inflammation in HF and that probenecid alleviates chronic HF by reducing inflammasome activation. The present translational study suggests the possibility of repositioning probenecid for HF indications. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Somatostatin and Its Receptors in Myocardial Ischemia/Reperfusion Injury and Cardioprotection.
- Author
-
Vörös, Imre, Sághy, Éva, Pohóczky, Krisztina, Makkos, András, Onódi, Zsófia, Brenner, Gábor B., Baranyai, Tamás, Ágg, Bence, Váradi, Barnabás, Kemény, Ágnes, Leszek, Przemyslaw, Görbe, Anikó, Varga, Zoltán V., Giricz, Zoltán, Schulz, Rainer, Helyes, Zsuzsanna, and Ferdinandy, Péter
- Abstract
Little is known about the role of the neuropeptide somatostatin (SST) in myocardial ischemia/reperfusion injury and cardioprotection. Here, we investigated the direct cardiocytoprotective effect of SST on ischemia/reperfusion injury in cardiomyocyte cultures, as well as the expression of SST and its receptors in pig and human heart tissues. SST induced a bell-shaped, concentration-dependent cardiocytoprotection in both adult rat primary cardiomyocytes and H9C2 cells subjected to simulated ischemia/reperfusion injury. Furthermore, in a translational porcine closed-chest acute myocardial infarction model, ischemic preconditioning increased plasma SST-like immunoreactivity. Interestingly, SST expression was detectable at the protein, but not at the mRNA level in the pig left ventricles. SSTR1 and SSTR2, but not the other SST receptors, were detectable at the mRNA level by PCR and sequencing in the pig left ventricle. Moreover, remote ischemic conditioning upregulated SSTR1 mRNA. Similarly, SST expression was also detectable in healthy human interventricular septum samples at the protein level. Furthermore, SST-like immunoreactivity decreased in interventricular septum samples of patients with ischemic cardiomyopathy. SSTR1, SSTR2, and SSTR5 but not SST and the other SST receptors were detectable at the mRNA level by sequencing in healthy human left ventricles. In addition, in healthy human left ventricle samples, SSTR1 and SSTR2 mRNAs were expressed especially in vascular endothelial and some other cell types as detected by RNA Scope® in situ hybridization. This is the first demonstration that SST exerts a direct cardiocytoprotective effect against simulated ischemia/reperfusion injury. Moreover, SST is expressed in the heart tissue at the peptide level; however, it is likely to be of sensory neural origin since its mRNA is not detectable. SSTR1 and SSTR2 might be involved in the cardioprotective action of SST, but other mechanisms cannot be excluded. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Glucose levels show independent and dose-dependent association with worsening acute pancreatitis outcomes: Post-hoc analysis of a prospective, international cohort of 2250 acute pancreatitis cases.
- Author
-
Nagy, Anikó, Juhász, Márk Félix, Görbe, Anikó, Váradi, Alex, Izbéki, Ferenc, Vincze, Áron, Sarlós, Patrícia, Czimmer, József, Szepes, Zoltán, Takács, Tamás, Papp, Mária, Fehér, Eszter, Hamvas, József, Kárász, Klaudia, Török, Imola, Stimac, Davor, Poropat, Goran, Ince, Ali Tüzün, Erőss, Bálint, and Márta, Katalin
- Abstract
Metabolic risk factors, such as obesity, hypertension, and hyperlipidemia are independent risk factors for the development of various complications in acute pancreatitis (AP). Hypertriglyceridemia dose-dependently elicits pancreatotoxicity and worsens the outcomes of AP. The role of hyperglycemia, as a toxic metabolic factor in the clinical course of AP, has not been examined yet. We analyzed a prospective, international cohort of 2250 AP patients, examining associations between (1) glycosylated hemoglobin (HbA1c), (2) on-admission glucose, (3) peak in-hospital glucose and clinically important outcomes (mortality, severity, complications, length of hospitalization (LOH), maximal C-reactive protein (CRP)). We conducted a binary logistic regression accounting for age, gender, etiology, diabetes, and our examined variables. Receiver Operating Characteristic Curve (ROC) was applied to detect the diagnostic accuracy of the three variables. Both on-admission and peak serum glucose are independently associated with AP severity and mortality, accounting for age, gender, known diabetes and AP etiology. They show a dose-dependent association with severity (p < 0.001 in both), mortality (p < 0.001), LOH (p < 0.001), maximal CRP (p < 0.001), systemic (p < 0.001) and local complications (p < 0.001). Patients with peak glucose >7 mmol/l had a 15 times higher odds for severe AP and a five times higher odds for mortality. We found a trend of increasing HbA1c with increasing LOH (p < 0.001), severity and local complications. On-admission and peak in-hospital glucose are independently and dose-dependently associated with increasing AP severity and mortality. In-hospital laboratory control of glucose and adequate treatment of hyperglycemia are crucial in the management of AP. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Reduction in hypoxia‐reoxygenation‐induced myocardial mitochondrial damage with exogenous methane.
- Author
-
Jász, Dávid Kurszán, Szilágyi, Ágnes Lilla, Tuboly, Eszter, Baráth, Bálint, Márton, Anett Roxána, Varga, Petra, Varga, Gabriella, Érces, Dániel, Mohácsi, Árpád, Szabó, Anna, Bozó, Renáta, Gömöri, Kamilla, Görbe, Anikó, Boros, Mihály, and Hartmann, Petra
- Subjects
MITOCHONDRIA ,CYTOCHROME c ,MEMBRANE potential ,MITOCHONDRIAL membranes ,OXYGEN consumption - Abstract
Albeit previous experiments suggest potential anti‐inflammatory effect of exogenous methane (CH4) in various organs, the mechanism of its bioactivity is not entirely understood. We aimed to investigate the potential mitochondrial effects and the underlying mechanisms of CH4 in rat cardiomyocytes and mitochondria under simulated ischaemia/reperfusion (sI/R) conditions. Three‐day‐old cultured cardiomyocytes were treated with 2.2% CH4‐artificial air mixture during 2‐hour‐long reoxygenation following 4‐hour‐long anoxia (sI/R and sI/R + CH4, n = 6‐6), with normoxic groups serving as controls (SH and SH + CH4; n = 6‐6). Mitochondrial functions were investigated with high‐resolution respirometry, and mitochondrial membrane injury was detected by cytochrome c release and apoptotic characteristics by using TUNEL staining. CH4 admixture had no effect on complex II (CII)‐linked respiration under normoxia but significantly decreased the complex I (CI)‐linked oxygen consumption. Nevertheless, addition of CH4 in the sI/R + CH4 group significantly reduced the respiratory activity of CII in contrast to CI and the CH4 treatment diminished mitochondrial H2O2 production. Substrate‐induced changes to membrane potential were partially preserved by CH4, and additionally, cytochrome c release and apoptosis of cardiomyocytes were reduced in the CH4‐treated group. In conclusion, the addition of CH4 decreases mitochondrial ROS generation via blockade of electron transport at CI and reduces anoxia‐reoxygenation‐induced mitochondrial dysfunction and cardiomyocyte injury in vitro. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Characterization of the CDAA Diet-Induced Non-alcoholic Steatohepatitis Model: Sex-Specific Differences in Inflammation, Fibrosis, and Cholesterol Metabolism in Middle-Aged Mice.
- Author
-
Kucsera, Dániel, Tóth, Viktória E., Gergő, Dorottya, Vörös, Imre, Onódi, Zsófia, Görbe, Anikó, Ferdinandy, Péter, and Varga, Zoltán V.
- Subjects
CHOLESTEROL metabolism ,NON-alcoholic fatty liver disease ,DYSLIPIDEMIA ,DISEASE risk factors ,LABORATORY mice ,KUPFFER cells - Abstract
Background: The prevalence of non-alcoholic steatohepatitis (NASH) rapidly increases with associated metabolic disorders such as dyslipidemia; therefore, NASH is now considered an independent risk factor of cardiovascular diseases. NASH displays sex-linked epidemiological, phenotypical, and molecular differences; however, little is known about the background of these sex-specific differences on the molecular level. Objectives: We aimed to assess sex-specific differences in the expression of inflammatory and fibrotic genes, as well as in cholesterol metabolism, focusing on the expression of Pcsk9 in several tissues in a mouse model of NASH that shows the typical features of the human condition. Methods and Results: We fed 10-months-old male and female C57Bl/6J mice with a NASH-inducing CDAA or corresponding control diet for 8 weeks. We found that, compared to the control male mice baseline, hepatic Pcsk9 expression as well as serum PCSK9 level was significantly higher in females, and both circulating PCSK9 level and the hepatic Pcsk9 gene were markedly decreased in female mice during NASH development. Histological analysis revealed that male and female mice develop a similar degree of steatosis; however, fibrosis was more pronounced in males upon CDAA diet feeding. Strikingly, female mice have higher hepatic expression of the pro-inflammatory cytokines (Il1b, Ifng), and increased IL-1β cleavage by the NLRP3 inflammasome, and a decrease in Clec4f
+ resident Kupffer cell population in comparison to males in the CDAA-fed groups. Conclusion: This is the first demonstration that there are critical sex-specific differences during NASH development in middle-aged mice regarding inflammation, fibrosis, and cholesterol metabolism and that changes in PCSK9 and IL-1β are likely important contributors to sex-specific changes during the transition to NASH. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
24. Myocardial ischaemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options.
- Author
-
Bencsik, Péter, Gömöri, Kamilla, Szabados, Tamara, Sántha, Péter, Helyes, Zsuzsanna, Jancsó, Gábor, Ferdinandy, Péter, and Görbe, Anikó
- Subjects
MYOCARDIAL reperfusion ,ISCHEMIC preconditioning ,REPERFUSION injury ,CARDIOVASCULAR diseases risk factors ,NEUROPATHY ,ISCHEMIC conditioning ,HEART diseases - Abstract
During the last decades, mortality from acute myocardial infarction has been dramatically reduced. However, the incidence of post-infarction heart failure is still increasing. Cardioprotection by ischaemic conditioning had been discovered more than three decades ago. Its clinical translation, however, is still an unmet need. This is mainly due to the disrupted cardioprotective signalling pathways in the presence of different cardiovascular risk factors, co-morbidities and the medication being taken. Sensory neuropathy is one of the co-morbidities that has been shown to interfere with cardioprotection. In the present review, we summarize the diverse aetiology of sensory neuropathies and the mechanisms by which these neuropathies may interfere with ischaemic heart disease and cardioprotective signalling. Finally, we suggest future therapeutic options targeting both ischaemic heart and sensory neuropathy simultaneously. LINKED ARTICLES: This article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.23/issuetoc. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Co‐expression of glycosylated aquaporin‐1 and transcription factor NFAT5 contributes to aortic stiffness in diabetic and atherosclerosis‐prone mice.
- Author
-
Madonna, Rosalinda, Doria, Vanessa, Görbe, Anikó, Cocco, Nino, Ferdinandy, Péter, Geng, Yong‐Jian, Pierdomenico, Sante Donato, and De Caterina, Raffaele
- Subjects
CYTOSKELETAL proteins ,TRANSCRIPTION factors ,GLYCOSYLATED hemoglobin ,NADPH oxidase ,MICE ,ARTERIAL diseases - Abstract
Increased stiffness characterizes the early change in the arterial wall with subclinical atherosclerosis. Proteins inducing arterial stiffness in diabetes and hypercholesterolaemia are largely unknown. This study aimed at determining the pattern of protein expression in stiffening aorta of diabetic and hypercholesterolaemic mice. Male Ins2+/Akita mice were crossbred with ApoE−/− (Ins2+/Akita: ApoE−/−) mice. Relative aortic distension (relD) values were determined by ultrasound analysis and arterial stiffness modulators by immunoblotting. Compared with age‐ and sex‐matched C57/BL6 control mice, the aortas of Ins2+/Akita, ApoE−/− and Ins2+/Akita:ApoE−/− mice showed increased aortic stiffness. The aortas of Ins2+/Akita, ApoE−/− and Ins2+/Akita:ApoE−/− mice showed greater expression of VCAM‐1, collagen type III, NADPH oxidase and iNOS, as well as reduced elastin, with increased collagen type III‐to‐elastin ratio. The aorta of Ins2+/Akita and Ins2+/Akita:ApoE−/− mice showed higher expression of eNOS and cytoskeletal remodelling proteins, such as F‐actin and α‐smooth muscle actin, in addition to increased glycosylated aquaporin (AQP)‐1 and transcription factor NFAT5, which control the expression of genes activated by high glucose‐induced hyperosmotic stress. Diabetic and hypercholesterolaemic mice have increased aortic stiffness. The association of AQP1 and NFAT5 co‐expression with aortic stiffness in diabetes and hypercholesterolaemia may represent a novel molecular pathway or therapeutic target. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. A Comorbidity Model of Myocardial Ischemia/Reperfusion Injury and Hypercholesterolemia in Rat Cardiac Myocyte Cultures.
- Author
-
Makkos, András, Szántai, Ágnes, Pálóczi, János, Pipis, Judit, Kiss, Bernadett, Poggi, Paola, Ferdinandy, Péter, Chatgilialoglu, Alexandros, and Görbe, Anikó
- Subjects
REPERFUSION injury ,CORONARY disease ,HYPERCHOLESTEREMIA ,CELL death ,COMORBIDITY - Abstract
Introduction: The use of comorbidity models is crucial in cardioprotective drug development. Hypercholesterolemia causes endothelial and myocardial dysfunction, as well as aggravates ischemia/reperfusion (I/R)-induced myocardial injury. Endogenous cardioprotective mechanisms against I/R are impaired in hyperlipidemic and hyperglycemic in vivo animal models. Therefore, our aim was to develop a medium throughput comorbidity cell-based test system of myocardial I/R injury, hypercholesterolemia and hyperglycemia that mimics comorbidity conditions. Methods: Cardiac myocytes isolated from neonatal or adult rat hearts were cultured in control or in three different hypercholesterolemic media with increasing cholesterol content (hiChol) or hiChol + hyperglycemic medium, respectively. Each group was then subjected to simulated ischemia/reperfusion (SI/R) or corresponding normoxic condition, respectively. Cholesterol uptake was tested by Filipin staining in neonatal cardiac myocytes. Cell viability, total cell count and oxidative stress, i.e., total reactive oxygen species (ROS) and superoxide level were measured by fluorescent assays. Results: Neonatal cardiac myocytes took up cholesterol from the different hiChol media at a concentration-dependent manner. In normoxia, viability of hiChol neonatal cardiac myocytes was not significantly changed, however, superoxide levels were increased as compared to vehicle. After SI/R, the viability of hiChol neonatal cardiac myocytes was decreased and total ROS level was increased as compared to vehicle. HiChol combined with hyperglycemia further aggravated cell death and oxidative stress in normoxic as well as in SI/R conditions. Viability of hiChol adult cardiac myocytes was significantly decreased and superoxide level was increased in normoxia and these changes were further aggravated by SI/R. HiChol combined with hyperglycemia further aggravated cell death, however level of oxidative stress increased only in normoxic condition. Conclusion: HiChol rat cardiac myocytes showed reduction of cell viability and increased oxidative stress, which were further aggravated by SI/R and with additional hyperglycemia. This is the first demonstration that the combination of the current hypercholesterolemic medium and SI/R in cardiac myocytes mimics the cardiac pathology of the comorbid heart with I/R and hypercholesterolemia. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.
- Author
-
Andreadou, Ioanna, Iliodromitis, Efstathios K, Lazou, Antigone, Görbe, Anikó, Giricz, Zoltán, Schulz, Rainer, Ferdinandy, Péter, Görbe, Anikó, Giricz, Zoltán, and Ferdinandy, Péter
- Subjects
HYPERCHOLESTEREMIA ,CARDIOVASCULAR diseases risk factors ,ATHEROSCLEROSIS ,REPERFUSION injury ,GENE expression ,APOPTOSIS ,CELLULAR signal transduction ,CLINICAL trials ,CORONARY heart disease prevention ,HEART metabolism ,CORONARY disease ,MYOCARDIAL reperfusion complications ,THERAPEUTICS ,PREVENTION - Abstract
Hypercholesterolaemia is considered to be a principle risk factor for cardiovascular disease, having direct negative effects on the myocardium itself, in addition to the development of atherosclerosis. Since hypercholesterolaemia affects the global cardiac gene expression profile, among many other factors, it results in increased myocardial oxidative stress, mitochondrial dysfunction and inflammation triggered apoptosis, all of which may account for myocardial dysfunction and increased susceptibility of the myocardium to infarction. In addition, numerous experimental and clinical studies have revealed that hyperlcholesterolaemia may interfere with the cardioprotective potential of conditioning mechanisms. Although not fully elucidated, the underlying mechanisms for the lost cardioprotection in hypercholesterolaemic animals have been reported to involve dysregulation of the endothelial NOS-cGMP, reperfusion injury salvage kinase, peroxynitrite-MMP2 signalling pathways, modulation of ATP-sensitive potassium channels and apoptotic pathways. In this review article, we summarize the current knowledge on the effect of hypercholesterolaemia on the non-ischaemic and ischaemic heart as well as on the cardioprotection induced by drugs or ischaemic preconditioning, postconditioning and remote conditioning. Future perspectives concerning the mechanisms and the design of preclinical and clinical trials are highlighted.
Linked Articles: This article is part of a themed section on Redox Biology and Oxidative Stress in Health and Disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.12/issuetoc. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
28. Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications.
- Author
-
Ferdinandy, Péter, Baczkó, István, Bencsik, Péter, Giricz, Zoltán, Görbe, Anikó, Pacher, Pál, Varga, Zoltán V, Varró, András, and Schulz, Rainer
- Published
- 2019
- Full Text
- View/download PDF
29. Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection.
- Author
-
Bencsik, Péter, Kupai, Krisztina, Görbe, Anikó, Kenyeres, Éva, Varga, Zoltán V., Pálóczi, János, Gáspár, Renáta, Kovács, László, Weber, Lutz, Takács, Ferenc, Hajdú, István, Fabó, Gabriella, Cseh, Sándor, Barna, László, Csont, Tamás, Csonka, Csaba, Dormán, György, and Ferdinandy, Péter
- Subjects
MATRIX metalloproteinase inhibitors ,CARBOXYLIC acid derivatives - Abstract
The objective of our present study is to develop novel inhibitors for MMP-2 for acute cardioprotection. In a series of pilot studies, novel substituted carboxylic acid derivatives were synthesized based on imidazole and thiazole scaffolds and then tested in a screeening cascade for MMP inhibition. We found that the MMP-inhibiting effects of imidazole and thiazole carboxylic acid-based compounds are superior in efficacy in comparison to the conventional hydroxamic acid derivatives of the same molecules. Based on these results, a 568-membered focused library of imidazole and thiazole compounds was generated in silico and then the library members were docked to the 3D model of MMP-2 followed by an in vitro medium throughput screening (MTS) based on a fluorescent assay employing MMP-2 catalytic domain. Altogether 45 compounds showed a docking score of >70, from which 30 compounds were successfully synthesized. Based on theMMP-2 inhibitory tests using gelatin zymography, 7 compounds were then selected and tested in neonatal rat cardiac myocytes subjected to simulated I/R injury. Six compounds showed significant cardio-cytoprotecion and the most effective compound (MMPI-1154) significantly decreased infarct size when applied at 1µM in an ex vivo model for acute myocardial infarction. This is the first demonstration that imidazole and thiazole carboxylic acid-based compounds are more efficacious MMP-2 inhibitor than their hydroxamic acid derivatives. MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid MMP-2 inhibitor lead candidate for the treatment of acute myocardial infarction. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. Targeting Mitochondrial Dysfunction with L-Alpha Glycerylphosphorylcholine.
- Author
-
Strifler, Gerda, Tuboly, Eszter, Görbe, Anikó, Boros, Mihály, Pécz, Daniella, and Hartmann, Petra
- Subjects
GLYCERYLPHOSPHORYLCHOLINE ,MITOCHONDRIAL pathology ,MYELOPEROXIDASE ,XANTHINE ,LABORATORY rats - Abstract
Background: We hypothesized that L-alpha-glycerylphosphorylcholine (GPC), a deacylatedphosphatidylcholine derivative, can influence the mitochondrial respiratory activity and in this way, may exert tissue protective effects. Methods: Rat liver mitochondria were examined with high-resolution respirometry to analyze the effects of GPC on the electron transport chain in normoxic and anoxic conditions. Besides, Sprague-Dawley rats were subjected to sham operation or standardized liver ischemia-reperfusion (IR), with or without GPC administration. The reduced glutathione (GSH) and oxidized glutathione disulfide (GSSG), the tissue myeloperoxidase, xanthine oxidoreductase and NADPH oxidases activities were measured. Tissue malondialdehyde and nitrite/nitrate formation, together with blood superoxide and hydrogen-peroxide production were assessed. Results: GPC increased the efficacy of complex I-linked mitochondrial oxygen consumption, with significantly lower in vitro leak respiration. Mechanistically, liver IR injury was accompanied by deteriorated mitochondrial respiration and enhanced ROS production and, as a consequence, by significantly increased inflammatory enzyme activities. GPC administration decreased the inflammatory activation in line with the reduced oxidative and nitrosative stress markers. Conclusion: GPC, by preserving the mitochondrial complex I function respiration, reduced the biochemical signs of oxidative stress after an IR episode. This suggests that GPC is a mitochondria-targeted compound that indirectly suppresses the activity of major intracellular superoxide-generating enzymes. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
31. Exogenous Nitric Oxide Protects Human Embryonic Stem Cell-Derived Cardiomyocytes against Ischemia/Reperfusion Injury.
- Author
-
Pálóczi, János, Varga, Zoltán V., Apáti, Ágota, Szebényi, Kornélia, Sarkadi, Balázs, Madonna, Rosalinda, De Caterina, Raffaele, Csont, Tamás, Eschenhagen, Thomas, Ferdinandy, Péter, and Görbe, Anikó
- Published
- 2016
- Full Text
- View/download PDF
32. Activation of PPARβ/δ protects cardiac myocytes from oxidative stress-induced apoptosis by suppressing generation of reactive oxygen/nitrogen species and expression of matrix metalloproteinases.
- Author
-
Barlaka, Eleftheria, Görbe, Anikó, Gáspár, Renáta, Pálóczi, János, Ferdinandy, Péter, and Lazou, Antigone
- Subjects
- *
PEROXISOME proliferator-activated receptors , *HEART cells , *OXIDATIVE stress , *ACTIVE oxygen in the body , *MATRIX metalloproteinases , *GENE expression , *THERAPEUTICS , *PREVENTION ,APOPTOSIS prevention - Abstract
Heart failure still remains one of the leading causes of morbidity and mortality worldwide. A major contributing factor is reactive oxygen/nitrogen species (RONS) overproduction which is associated with cardiac remodeling partly through cardiomyocyte apoptosis. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear receptor superfamily and have been implicated in cardioprotection. However, the molecular mechanisms are largely unexplored. In this study we sought to investigate the potential beneficial effects evoked by activation of PPARβ/δ under the setting of oxidative stress induced by H 2 O 2 in adult rat cardiac myocytes. The selective PPARβ/δ agonist GW0742 inhibited the H 2 O 2 -induced apoptosis and increased cell viability. In addition, generation of RONS was attenuated in cardiac myocytes in the presence of PPARβ/δ agonist. These effects were abolished in the presence of the PPARβ/δ antagonist indicating that the effect was through PPARβ/δ receptor activation. Treatment with PPARβ/δ agonist was also associated with attenuation of caspase-3 and PARP cleavage, upregulation of anti-apoptotic Bcl-2 and concomitant downregulation of pro-apoptotic Bax. In addition, activation of PPARβ/δ inhibited the oxidative-stress-induced MMP-2 and MMP-9 mRNA upregulation. It is concluded that PPARβ/δ activation exerts a cytoprotective effect in adult rat cardiac myocytes subjected to oxidative stress via inhibition of oxidative stress, MMP expression, and apoptosis. Our data suggest that the novel connection between PPAR signaling and MMP down-regulation in cardiac myocytes might represent a new target for the management of oxidative stress-induced cardiac dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
33. MicroRNAs associated with ischemia-reperfusion injury and cardioprotection by ischemic pre- and postconditioning: protectomiRs.
- Author
-
Varga, Zoltán V., Zvara, Ágnes, Faragó, Nóra, Kocsis, Gabriella F., Pipicz, Márton, Gáspár, Renáta, Bencsik, Péter, Görbe, Anikó, Csonka, Csaba, Puskás, László G., Thum, Thomas, Csont, Tamás, and Ferdinandy, Péter
- Subjects
MICRORNA ,REPERFUSION injury ,ISCHEMIA ,DNA microarrays ,ARTERIAL occlusions ,CARDIOTONIC agents - Abstract
We aimed to characterize early
changes in microRNA expression in acute cardioprotection by ischemic pre- and postconditioning in rat hearts. Hearts isolated from male Wistar rats were subjected to 1) time-matched nonischemic perfusion, 2) ischemia-reperfusion (30 min of coronary occlusion and 120 min of reperfusion), 3) preconditioning (3 × 5 min of coronary occlusion) followed by ischemia-reperfusion, or 4) ischemia-reperfusion with postconditioning (6 × 10 s of global ischemia-reperfusion at the onset of reperfusion). Infarct size was significantly reduced by both interventions. Of 350 different microRNAs assessed by microarray analysis, 147-160 microRNAs showed detectable expression levels. Compared with microRNA alterations induced by ischemia-reperfusion versus time-matched nonischemic controls, five microRNAs were significantly affected by both pre- and postconditioning (microRNA- 125b*, microRNA-139-3p, microRNA-320, microRNA-532-3p, and microRNA-188), four microRNAs were significantly affected by preconditioning (microRNA-487b, microRNA-139-5p, microRNA- 192, and microRNA-212), and nine microRNAs were significantly affected by postconditioning (microRNA-1, microRNA let-7i, microRNA let-7e, microRNA let-7b, microRNA-181a, microRNA-208, microRNA- 328, microRNA-335, and microRNA-503). Expression of randomly selected microRNAs was validated by quantitative real-time PCR. By a systematic comparison of the direction of microRNA expression changes in all groups, we identified microRNAs, specific mimics, or antagomiRs that may have pre- and postconditioning-like cardioprotective effects (protectomiRs). Transfection of selected protectomiRs (mimics of microRNA-139-5p, microRNA-125b*, microRNA let-7b, and inhibitor of microRNA-487b) into cardiac myocytes subjected to simulated ischemia-reperfusion showed a significant cytoprotective effect. This is the first demonstration that the ischemiareperfusion- induced microRNA expression profile is significantly influenced by both pre- and postconditioning, which shows the involvement of microRNAs in cardioprotective signaling. Moreover, by analysis of microRNA expression patterns in cardioprotection by preand postconditioning, specific protectomiRs can be revealed as potential therapeutic tools for the treatment of ischemia-reperfusion injury. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
34. Therapeutic potential of midkine in cardiovascular disease.
- Author
-
Kadomatsu, Kenji, Bencsik, Péter, Görbe, Anikó, Csonka, Csaba, Sakamoto, Kazuma, Kishida, Satoshi, and Ferdinandy, Péter
- Abstract
Unlabelled: Ischaemic heart disease, stroke and their pathological consequences are life-threatening conditions that account for about half of deaths in developed countries. Pathology of these diseases includes cell death due to ischaemia/reperfusion injury, vascular stenosis and cardiac remodelling. The growth factor midkine plays a pivotal role in these events. Midkine shows an acute cytoprotective effect in ischaemia/reperfusion injury at least in part via its anti-apoptotic effect. Moreover, while midkine promotes endothelial cell proliferation, it also recruits inflammatory cells to lesions. These activities eventually enhance angiogenesis, thereby preventing cardiac tissue remodelling. However, midkine's activity in recruiting inflammatory cells into the vascular wall also triggers neointima formation, and consequently, vascular stenosis. Moreover, midkine is induced in cancer tissues where it enhances angiogenesis. Therefore, midkine may promote tumour formation through its angiogenic and anti-apoptotic activity. This review focuses on the roles of midkine in ischaemic cardiovascular disease and their pathological consequences, that is angiogenesis, vascular stenosis, and cardiac remodelling, and discusses the possible therapeutic potential of modulation of midkine in these diseases.Linked Articles: This article is part of a themed section on Midkine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-4. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
35. Cholesterol-enriched diet inhibits cardioprotection by ATP-sensitive K+ channel activators cromakalim and diazoxide.
- Author
-
Csonka, Csaba, Kupai, Krisztina, Bencsik, Péter, Görbe, Anikó, Pálóczi, János, Zvara, Ágnes, Puskás, László G., Csont, Tamás, and Ferdinandy, Péter
- Subjects
CHOLESTEROL ,HYPERLIPIDEMIA ,ISCHEMIA ,DIAZOXIDE ,GLIBENCLAMIDE ,ENERGY metabolism ,OXIDATIVE stress ,POTASSIUM channels regulation - Abstract
It has been previously shown that hyperlipidemia interferes with cardioprotective mechanisms. Here, we investigated the interaction of hyperlipidemia with cardioprotection induced by pharmacological activators of ATPsensitive K
+ (KATP ) channels. Hearts isolated from rats fed a 2% cholesterol-enriched diet or normal diet for 8 wk were subjected to 30 min of global ischemia and 120 min of reperfusion in the presence or absence of KATP modulators. In normal diet-fed rats, either the nonselective KATP activator cromakalim at 10-5 M or the selective mitochondrial (mito)KATP opener diazoxide at 3 × 10-5 M significantly decreased infarct size compared with vehicle-treated control rats. Their cardioprotective effect was abolished by coadministration of the nonselective KATP blocker glibenclamide or the selective mitoKATP blocker 5-hydroxydecanoate, respectively. However, in cholesterol-fed rats, the cardioprotective effect of cromakalim or diazoxide was not observed. Therefore, we further investigated how cholesterol-enriched diet influences cardiac KATP channels. Cardiac expression of a KATP subunit gene (Kir6.1) was significantly downregulated in cholesterol-fed rats; however, protein levels of Kir6.1 and Kir6.2 were not changed. The cholesterol diet significantly decreased cardiac ATP, increased lactate content, and enhanced myocardial oxidative stress, as shown by increased cardiac superoxide and dityrosine formation. This is the first demonstration that cardioprotection by KATP channel activators is impaired in cholesterol-enriched dietinduced hyperlipidemia. The background mechanism may include hyperlipidemia-induced attenuation of mitoKATP function by altered energy metabolism and increased oxidative stress in the heart. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
36. Cholesterol diet leads to attenuation of ischemic preconditioning-induced cardiac protection: the role of connexin 43.
- Author
-
Görbe, Anikó, Varga, Zoltán V., Kupai, Krisztina, Bencsik, Péter, Kocsis, Gabriella F., Csont, Tamás, Boengler, Kerstin, Schulz, Rainer, and Ferdinandy, Péter
- Subjects
- *
LOW-cholesterol diet , *MITOCHONDRIA , *SARCOLEMMA , *HYPERLIPIDEMIA , *SUPEROXIDES - Abstract
Cardioprotection by ischemic preconditioning (IP) was abolished in connexin 43 (Cx43)-deficient mice due to loss of Cx43 located in mitochondria rather than at the sarcolemma. IP is lost in hyperlipidemic rat hearts as well. Since changes in mitochondrial Cx43 in hyperlipidemia have not yet been analyzed, we determined total and mitochondrial Cx43 levels in male Wistar rats fed a laboratory chow enriched with 2% cholesterol or normal chow for 12 wk. Hearts were isolated and perfused according to Langendorff. After a 10-min perfusion, myocardial tissue cholesterol, superoxide, and nitrotyrosine contents were measured and Cx43 content in whole heart homogenate and a mitochondrial fraction determined. In the cholesterol-fed group, tissue cholesterol and superoxide formation was increased (P < 0.05), while total Cx43 content remained unchanged. Mitochondrial total and dephosphorylated Cx43 content decreased. Hearts were subjected to an IP protocol (3 × 5 min ischemia-reperfusion) or time-matched aerobic perfusion followed by 30-min global ischemia and 5-min reperfusion. IP reduced infarct size in normal but not in cholesterol-fed rats. At 5-min reperfusion following 30-min global ischemia, the total and dephosphorylated mitochondrial Cx43 content was increased, which was abolished by IP in both normal and high-cholesterol diet. In conclusion, loss of cardioprotection by IP in hyperlipidemia is associated with a redistribution of both sarcolemmal and mitochondrial Cx43. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
37. Role of iNOS and peroxynitrite—matrix metalloproteinase-2 signaling in myocardial late preconditioning in rats.
- Author
-
Bencsik, Peter, Kupai, Krisztina, G!ricz, Zoltán, Görbe, Anikó, Pipis, Judit, Murlasits, Zsolt, Kocsis, Gabriella F., Varga-Orvos, Zoltán, Puskás, László G., Csonka, Csaba, Csont, Tamás, and Ferdinandy, Peter
- Subjects
METALLOPROTEINASES ,NITRIC oxide ,GENE expression ,SUPEROXIDES ,LABORATORY rats ,SUPEROXIDE dismutase ,ISCHEMIA ,ARRHYTHMIA - Abstract
We have previously shown that the inhibition of myocardial nitric oxide (NO) and peroxynitrite-matrix metalloproteinase (MMP) signaling by early preconditioning (PC) is involved in its cardioprotective effect. Therefore, in the present study, we investigated the role of NO and peroxynitrite-MMP signaling in the development of late PC. PC was performed by five consecutive cycles of 4-mm coronary occlusion and 4-mm reperfusion in anesthetized rats in vivo. Twenty-four hours later, hearts were subjected to a 30-mm coronary occlusion followed by I 80-mm reperfusion to measure infarct size. In separate experiments, heart tissue was sampled to measure biochemical parameters before and 3, 6, 12, or 24 h after the PC protocol, respectively. Late PC decreased infarct size, increased cardiac inducible NO synthase (iNOS) activity and gene expression, and decreased SOD activity at 24 h significantly compared with sham-operated controls. Late PC increased cardiac superoxide levels significantly at 24 h; however, it did not change cardiac NO levels. Cardiac peroxynitrite levels were significantly decreased. Downstream cellular targets of peroxynitrite, MMP-2 and MMP-9 activities were decreased in the late PC group at 24 h compared with the sham-operated group. To verify if PC-induced inhibition of MMPs had a causative role in the reduction of infarct size, in separate experiments, we measured infarct size after the pharmacological inhibition of MMPs by ilomastat and found a significant reduction of infarct size compared with the vehicle-treated group. In conclusion, this is the first demonstration that the inhibition of cardiac peroxynitrite-MMP signaling contributes to cardioprotection by late PC and that pharmacological inhibition of MMPs is able to reduce infarct size in vivo. Furthermore, increased expression of iNOS may play a role in the development of late PC; however, increased iNOS activity does not lead to increased NO production in late PC. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
38. Biglycan protects cardiomyocytes against hypoxia/reoxygenation injury: Role of nitric oxide
- Author
-
Csont, Tamás, Görbe, Anikó, Bereczki, Erika, Szunyog, Andrea, Aypar, Eda, Tóth, Melinda E., Varga, Zoltán V., Csonka, Csaba, Fülöp, Ferenc, Sántha, Miklós, and Ferdinandy, Péter
- Subjects
- *
PROTEOGLYCANS , *HEART cells , *HYPOXEMIA , *NITRIC oxide , *ATHEROSCLEROSIS , *TRANSGENIC mice , *CARDIOTONIC agents , *MUSCLE cells - Abstract
Abstract: Biglycan, a proteoglycan component of extracellular matrix, has been suspected to contribute to the development of atherosclerosis, but overexpression of biglycan in transgenic mice has been shown to induce cardioprotective genes including nitric oxide (NO) synthases in the heart. Therefore, here we hypothesized if exogenous administration of biglycan exerts cytoprotection. Primary cardiomyocytes from neonatal rats were subjected to 150 min hypoxia and 2 h reoxygenation. Mortality of cardiomyocytes was dose-dependently attenuated by pretreatment with 1–100 nM biglycan. Biglycan enhanced eNOS mRNA and protein, and significantly increased NO content of cardiomyocytes. The NO synthase inhibitor l-nitro-arginine-methyl-ester significantly attenuated the cytoprotective effect of biglycan. This is the first demonstration that biglycan leads to cytoprotection against hypoxia/reoxygenation injury, and that this phenomenon is partially mediated by an NO-dependent mechanism. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
39. Hypercholesterolemia increases myocardial oxidative and nitrosative stress thereby leading to cardiac dysfunction in apoB-100 transgenic mice
- Author
-
Csont, Tamás, Bereczki, Erika, Bencsik, Péter, Fodor, Gabriella, Görbe, Anikó, Zvara, Ágnes, Csonka, Csaba, Puskás, László G., Sántha, Miklós, and Ferdinandy, Péter
- Subjects
HYPERCHOLESTEREMIA ,HEART failure ,CARDIAC arrest ,BLOOD plasma - Abstract
Abstract: Objective: We have previously shown that cholesterol diet-induced hyperlipidemia (marked hypertriglyceridemia and moderate hypercholesterolemia) increases cardiac formation of peroxynitrite and results in a moderate cardiac dysfunction in rats. Here our aim was to further clarify the mechanism of hyperlipidemia-induced nitrosative stress in a transgenic mouse model and to test if high cholesterol or high triglyceride is responsible for the hyperlipidemia-induced cardiac dysfunction. Methods and results: To determine the effect of cholesterol-enriched diet on cardiac performance and oxidative/nitrosative stress, wildtype and human apoB100 transgenic mice were fed a 2% cholesterol-enriched or a normal diet for 18 weeks. Serum cholesterol and LDL-cholesterol levels were significantly elevated only in the cholesterol-fed apoB100 transgenic mice, while serum triglycerides were increased in the transgenic mice fed a normal diet. Cholesterol-enriched diet significantly increased cardiac superoxide generation and NADPH oxidase expression and activity in apoB100 mice but not in wildtypes. Cardiac NO content and NO synthase activity did not change in either group. As assessed in isolated working hearts, aortic flow was significantly decreased only in apoB100 transgenic mice fed a cholesterol-enriched diet. The peroxynitrite decomposition catalyst FeTPPS attenuated the decrease in aortic flow in cholesterol-fed apoB100 mice. Immunohistochemistry showed elevated nitrotyrosine in the hearts of apoB100 mice fed the cholesterol-enriched diet. Conclusions: We conclude that hypercholesterolemia but not hypertriglyceridemia leads to increased formation of superoxide and peroxynitrite, and thereby results in cardiac dysfunction in hearts of human apoB100 transgenic mice. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
40. Helium Conditioning Increases Cardiac Fibroblast Migration Which Effect Is Not Propagated via Soluble Factors or Extracellular Vesicles.
- Author
-
Jelemenský, Marek, Kovácsházi, Csenger, Ferenczyová, Kristína, Hofbauerová, Monika, Kiss, Bernadett, Pállinger, Éva, Kittel, Ágnes, Sayour, Viktor Nabil, Görbe, Anikó, Pelyhe, Csilla, Hambalkó, Szabolcs, Kindernay, Lucia, Barančík, Miroslav, Ferdinandy, Péter, Barteková, Monika, and Giricz, Zoltán
- Subjects
MYOCARDIAL reperfusion ,EXTRACELLULAR vesicles ,HELIUM ,UMBILICAL veins ,ENDOTHELIAL cells ,REPERFUSION injury ,REPERFUSION ,FIBROBLASTS - Abstract
Helium inhalation induces cardioprotection against ischemia/reperfusion injury, the cellular mechanism of which remains not fully elucidated. Extracellular vesicles (EVs) are cell-derived, nano-sized membrane vesicles which play a role in cardioprotective mechanisms, but their function in helium conditioning (HeC) has not been studied so far. We hypothesized that HeC induces fibroblast-mediated cardioprotection via EVs. We isolated neonatal rat cardiac fibroblasts (NRCFs) and exposed them to glucose deprivation and HeC rendered by four cycles of 95% helium + 5% CO
2 for 1 h, followed by 1 h under normoxic condition. After 40 h of HeC, NRCF activation was analyzed with a Western blot (WB) and migration assay. From the cell supernatant, medium extracellular vesicles (mEVs) were isolated with differential centrifugation and analyzed with WB and nanoparticle tracking analysis. The supernatant from HeC-treated NRCFs was transferred to naïve NRCFs or immortalized human umbilical vein endothelial cells (HUVEC-TERT2), and a migration and angiogenesis assay was performed. We found that HeC accelerated the migration of NRCFs and did not increase the expression of fibroblast activation markers. HeC tended to decrease mEV secretion of NRCFs, but the supernatant of HeC or the control NRCFs did not accelerate the migration of naïve NRCFs or affect the angiogenic potential of HUVEC-TERT2. In conclusion, HeC may contribute to cardioprotection by increasing fibroblast migration but not by releasing protective mEVs or soluble factors from cardiac fibroblasts. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
41. Molecular Network Approach Reveals Rictor as a Central Target of Cardiac ProtectomiRs.
- Author
-
Makkos, András, Ágg, Bence, Varga, Zoltán V., Giricz, Zoltán, Gyöngyösi, Mariann, Lukovic, Dominika, Schulz, Rainer, Barteková, Monika, Görbe, Anikó, and Ferdinandy, Péter
- Subjects
MYOCARDIAL infarction ,DRUG target ,ISCHEMIC preconditioning ,ISCHEMIC postconditioning ,SWINE breeding - Abstract
Cardioprotective medications are still unmet clinical needs. We have previously identified several cardioprotective microRNAs (termed ProtectomiRs), the mRNA targets of which may reveal new drug targets for cardioprotection. Here we aimed to identify key molecular targets of ProtectomiRs and confirm their association with cardioprotection in a translational pig model of acute myocardial infarction (AMI). By using a network theoretical approach, we identified 882 potential target genes of 18 previously identified protectomiRs. The Rictor gene was the most central and it was ranked first in the protectomiR-target mRNA molecular network with the highest node degree of 5. Therefore, Rictor and its targeting microRNAs were further validated in heart samples obtained from a translational pig model of AMI and cardioprotection induced by pre- or postconditioning. Three out of five Rictor-targeting pig homologue of rat ProtectomiRs showed significant upregulation in postconditioned but not in preconditioned pig hearts. Rictor was downregulated at the mRNA and protein level in ischemic postconditioning but not in ischemic preconditioning. This is the first demonstration that Rictor is the central molecular target of ProtectomiRs and that decreased Rictor expression may regulate ischemic postconditioning-, but not preconditioning-induced acute cardioprotection. We conclude that Rictor is a potential novel drug target for acute cardioprotection. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
42. Cardioprotective microRNAs (protectomiRs) in a pig model of acute myocardial infarction and cardioprotection by ischaemic conditioning: MiR‐450a.
- Author
-
Nagy, Regina N., Makkos, András, Baranyai, Tamás, Giricz, Zoltán, Szabó, Márta, Kravcsenko‐Kiss, Bernadett, Bereczki, Zoltán, Ágg, Bence, Puskás, László G., Faragó, Nóra, Schulz, Rainer, Gyöngyösi, Mariann, Lukovic, Dominika, Varga, Zoltán V., Görbe, Anikó, and Ferdinandy, Péter
- Subjects
- *
GENE expression , *MYOCARDIAL infarction , *ISCHEMIC preconditioning , *LABORATORY rats , *ISCHEMIC conditioning - Abstract
Background and Purpose Experimental Approach Key Results Conclusion and Implications Cardioprotective miRNAs (protectomiRs) are promising therapeutic tools. Here, we aimed to identify protectomiRs in a translational porcine model of acute myocardial infarction (AMI) and to validate their cardiocytoprotective effect.ProtectomiR candidates were selected after systematic analysis of miRNA expression changes in cardiac tissue samples from a closed‐chest AMI model in pigs subjected to sham operation, AMI and ischaemic preconditioning, postconditioning or remote preconditioning, respectively. Cross‐species orthologue protectomiR candidates were validated in simulated ischaemia–reperfusion injury (sI/R) model of isolated rat ocardiomyocytes and in human AC16 cells as well. For miR‐450a, we performed target prediction and analysed the potential mechanisms of action by GO enrichment and KEGG pathway analysis.Out of the 220 detected miRNAs, four were up‐regulated and 10 were down‐regulated due to all three conditionings versus AMI. MiR‐450a and miR‐451 mimics at 25 nM were protective in rat cardiomyocytes, and miR‐450a showed protection in human cardiomyocytes as well. MiR‐450a has 3987 predicted mRNA targets in pigs, 4279 in rats and 8328 in humans. Of these, 607 genes are expressed in all three species. A total of 421 common enriched GO terms were identified in all three species, whereas KEGG pathway analysis revealed 13 common pathways.This is the first demonstration that miR‐450a is associated with cardioprotection by ischaemic conditioning in a clinically relevant porcine model and shows cardiocytoprotective effect in human cardiomyocytes, making it a promising drug candidate. The mechanism of action of miR‐450a involves multiple cardioprotective pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Calcium Ionophore-Induced Extracellular Vesicles Mediate Cytoprotection against Simulated Ischemia/Reperfusion Injury in Cardiomyocyte-Derived Cell Lines by Inducing Heme Oxygenase 1.
- Author
-
Pečan, Peter, Hambalkó, Szabolcs, Ha, Van Thai, Nagy, Csilla T., Pelyhe, Csilla, Lainšček, Duško, Kenyeres, Bence, Brenner, Gábor B., Görbe, Anikó, Kittel, Ágnes, Barteková, Monika, Ferdinandy, Péter, Manček-Keber, Mateja, and Giricz, Zoltán
- Subjects
HEME oxygenase ,REPERFUSION injury ,CYTOPROTECTION ,CELL lines ,MYOCARDIAL reperfusion ,ISCHEMIA ,EXTRACELLULAR vesicles - Abstract
Cardioprotection against ischemia/reperfusion injury is still an unmet clinical need. The transient activation of Toll-like receptors (TLRs) has been implicated in cardioprotection, which may be achieved by treatment with blood-derived extracellular vesicles (EVs). However, since the isolation of EVs from blood takes considerable effort, the aim of our study was to establish a cellular model from which cardioprotective EVs can be isolated in a well-reproducible manner. EV release was induced in HEK293 cells with calcium ionophore A23187. EVs were characterized and cytoprotection was assessed in H9c2 and AC16 cell lines. Cardioprotection afforded by EVs and its mechanism were investigated after 16 h simulated ischemia and 2 h reperfusion. The induction of HEK293 cells by calcium ionophore resulted in the release of heterogenous populations of EVs. In H9c2 and AC16 cells, stressEVs induced the downstream signaling of TLR4 and heme oxygenase 1 (HO-1) expression in H9c2 cells. StressEVs decreased necrosis due to simulated ischemia/reperfusion injury in H9c2 and AC16 cells, which was independent of TLR4 induction, but not that of HO-1. Calcium ionophore-induced EVs exert cytoprotection by inducing HO-1 in a TLR4-independent manner. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
44. Cardioprotective Effect of Novel Matrix Metalloproteinase Inhibitors.
- Author
-
Gömöri, Kamilla, Szabados, Tamara, Kenyeres, Éva, Pipis, Judit, Földesi, Imre, Siska, Andrea, Dormán, György, Ferdinandy, Péter, Görbe, Anikó, and Bencsik, Péter
- Subjects
MATRIX metalloproteinase inhibitors ,MATRIX effect ,REPERFUSION injury ,ISCHEMIC preconditioning ,CHOLIC acid - Abstract
Background: We recently developed novel matrix metalloproteinase-2 (MMP-2) inhibitor small molecules for cardioprotection against ischemia/reperfusion injury and validated their efficacy in ischemia/reperfusion injury in cardiac myocytes. The aim of the present study was to test our lead compounds for cardioprotection in vivo in a rat model of acute myocardial infarction (AMI) in the presence or absence of hypercholesterolemia, one of the major comorbidities affecting cardioprotection. Methods: Normocholesterolemic adult male Wistar rats were subjected to 30 min of coronary occlusion followed by 120 min of reperfusion to induce AMI. MMP inhibitors (MMPI)-1154 and -1260 at 0.3, 1, and 3 µmol/kg, MMPI-1248 at 1, 3, and 10 µmol/kg were administered at the 25th min of ischemia intravenously. In separate groups, hypercholesterolemia was induced by a 12-week diet (2% cholesterol, 0.25% cholic acid), then the rats were subjected to the same AMI protocol and single doses of the MMPIs that showed the most efficacy in normocholesterolemic animals were tested in the hypercholesterolemic animals. Infarct size/area at risk was assessed at the end of reperfusion in all groups by standard Evans blue and 2,3,5-triphenyltetrazolium chloride (TTC) staining, and myocardial microvascular obstruction (MVO) was determined by thioflavine-S staining. Results: MMPI-1154 at 1 µmol/kg, MMPI-1260 at 3 µmol/kg and ischemic preconditioning (IPC) as the positive control reduced infarct size significantly; however, this effect was not seen in hypercholesterolemic animals. MVO in hypercholesterolemic animals decreased by IPC only. Conclusions: This is the first demonstration that MMPI-1154 and MMPI-1260 showed a dose-dependent infarct size reduction in an in vivo rat AMI model; however, single doses that showed the most efficacy in normocholesterolemic animals were abolished by hypercholesterolemia. The further development of these promising cardioprotective MMPIs should be continued with different dose ranges in the study of hypercholesterolemia and other comorbidities. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
45. Decorin Protects Cardiac Myocytes against Simulated Ischemia/Reperfusion Injury.
- Author
-
Gáspár, Renáta, Gömöri, Kamilla, Kiss, Bernadett, Szántai, Ágnes, Pálóczi, János, Varga, Zoltán V., Pipis, Judit, Váradi, Barnabás, Ágg, Bence, Csont, Tamás, Ferdinandy, Péter, Barteková, Monika, and Görbe, Anikó
- Subjects
MYOCARDIAL reperfusion ,REPERFUSION injury ,MUSCLE cells ,ISCHEMIA ,CELL survival ,PROTEOGLYCANS - Abstract
Search for new cardioprotective therapies is of great importance since no cardioprotective drugs are available on the market. In line with this need, several natural biomolecules have been extensively tested for their potential cardioprotective effects. Previously, we have shown that biglycan, a member of a diverse group of small leucine-rich proteoglycans, enhanced the expression of cardioprotective genes and decreased ischemia/reperfusion-induced cardiomyocyte death via a TLR-4 dependent mechanism. Therefore, in the present study we aimed to test whether decorin, a small leucine-rich proteoglycan closely related to biglycan, could exert cardiocytoprotection and to reveal possible downstream signaling pathways. Methods: Primary cardiomyocytes isolated from neonatal and adult rat hearts were treated with 0 (Vehicle), 1, 3, 10, 30 and 100 nM decorin as 20 h pretreatment and maintained throughout simulated ischemia and reperfusion (SI/R). In separate experiments, to test the mechanism of decorin-induced cardio protection, 3 nM decorin was applied in combination with inhibitors of known survival pathways, that is, the NOS inhibitor L-NAME, the PKG inhibitor KT-5823 and the TLR-4 inhibitor TAK-242, respectively. mRNA expression changes were measured after SI/R injury. Results: Cell viability of both neonatal and adult cardiomyocytes was significantly decreased due to SI/R injury. Decorin at 1, 3 and 10 nM concentrations significantly increased the survival of both neonatal and adult myocytes after SI/R. At 3nM (the most pronounced protective concentration), it had no effect on apoptotic rate of neonatal cardiac myocytes. No one of the inhibitors of survival pathways (L-NAME, KT-5823, TAK-242) influenced the cardiocytoprotective effect of decorin. MYND-type containing 19 (Zmynd19) and eukaryotic translation initiation factor 4E nuclear import factor 1 (Eif4enif1) were significantly upregulated due to the decorin treatment. In conclusion, this is the first demonstration that decorin exerts a direct cardiocytoprotective effect possibly independent of NO-cGMP-PKG and TLR-4 dependent survival signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
46. Capsaicin-Sensitive Sensory Nerves and the TRPV1 Ion Channel in Cardiac Physiology and Pathologies.
- Author
-
Szabados, Tamara, Gömöri, Kamilla, Pálvölgyi, Laura, Görbe, Anikó, Baczkó, István, Helyes, Zsuzsanna, Jancsó, Gábor, Ferdinandy, Péter, and Bencsik, Péter
- Subjects
TRPV cation channels ,CORONARY disease ,ARRHYTHMIA ,ION channels ,PHYSIOLOGY ,MYOCARDIAL reperfusion ,HEART diseases - Abstract
Cardiovascular diseases, including coronary artery disease, ischemic heart diseases such as acute myocardial infarction and postischemic heart failure, heart failure of other etiologies, and cardiac arrhythmias, belong to the leading causes of death. Activation of capsaicin-sensitive sensory nerves by the transient receptor potential vanilloid 1 (TRPV1) capsaicin receptor and other receptors, as well as neuropeptide mediators released from them upon stimulation, play important physiological regulatory roles. Capsaicin-sensitive sensory nerves also contribute to the development and progression of some cardiac diseases, as well as to mechanisms of endogenous stress adaptation leading to cardioprotection. In this review, we summarize the role of capsaicin-sensitive afferents and the TRPV1 ion channel in physiological and pathophysiological functions of the heart based mainly on experimental results and show their diagnostic or therapeutic potentials. Although the actions of several other channels or receptors expressed on cardiac sensory afferents and the effects of TRPV1 channel activation on different non-neural cell types in the heart are not precisely known, most data suggest that stimulation of the TRPV1-expressing sensory nerves or stimulation/overexpression of TRPV1 channels have beneficial effects in cardiac diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
47. Cardiac miRNA Expression and their mRNA Targets in a Rat Model of Prediabetes.
- Author
-
Sághy, Éva, Vörös, Imre, Ágg, Bence, Kiss, Bernadett, Koncsos, Gábor, Varga, Zoltán V., Görbe, Anikó, Giricz, Zoltán, Schulz, Rainer, and Ferdinandy, Péter
- Subjects
STREPTOZOTOCIN ,PREDIABETIC state ,ZINC-finger proteins ,MESSENGER RNA ,MICRORNA ,NEPRILYSIN ,HIGH-fat diet - Abstract
Little is known about the mechanism of prediabetes-induced cardiac dysfunction. Therefore, we aimed to explore key molecular changes with transcriptomic and bioinformatics approaches in a prediabetes model showing heart failure with preserved ejection fraction phenotype. To induce prediabetes, Long-Evans rats were fed a high-fat diet for 21 weeks and treated with a single low-dose streptozotocin at week 4. Small RNA-sequencing, in silico microRNA (miRNA)-mRNA target prediction, Gene Ontology analysis, and target validation with qRT-PCR were performed in left ventricle samples. From the miRBase-annotated 752 mature miRNA sequences expression of 356 miRNAs was detectable. We identified two upregulated and three downregulated miRNAs in the prediabetic group. We predicted 445 mRNA targets of the five differentially expressed miRNAs and selected 11 mRNAs targeted by three differentially expressed miRNAs, out of which five mRNAs were selected for validation. Out of these five targets, downregulation of three mRNAs i.e., Juxtaposed with another zinc finger protein 1 (Jazf1); RAP2C, member of RAS oncogene family (Rap2c); and Zinc finger with KRAB and SCAN domains 1 (Zkscan1) were validated. This is the first demonstration that prediabetes alters cardiac miRNA expression profile. Predicted targets of differentially expressed miRNAs include Jazf1, Zkscan1, and Rap2c mRNAs. These transcriptomic changes may contribute to the diastolic dysfunction and may serve as drug targets. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
48. Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion.
- Author
-
Brenner, Gábor B., Makkos, András, Nagy, Csilla Terézia, Onódi, Zsófia, Sayour, Nabil V., Gergely, Tamás G., Kiss, Bernadett, Görbe, Anikó, Sághy, Éva, Zádori, Zoltán S., Lázár, Bernadette, Baranyai, Tamás, Varga, Richárd S., Husti, Zoltán, Varró, András, Tóthfalusi, László, Schulz, Rainer, Baczkó, István, Giricz, Zoltán, and Ferdinandy, Péter
- Subjects
MYOCARDIAL reperfusion ,ROFECOXIB ,CARDIOTOXICITY ,CLINICAL drug trials ,VENTRICULAR fibrillation ,REPERFUSION - Abstract
Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of 'hidden cardiotoxicity' is defined as cardiotoxicity of a drug that manifests in the diseased (e.g., ischemic/reperfused), but not in the healthy heart or as a drug-induced deterioration of cardiac stress adaptation (e.g., ischemic conditioning). Here, we aimed to test if the cardiotoxicity of a selective COX-2 inhibitor rofecoxib that was revealed during its clinical use, i.e., increased occurrence of proarrhythmic and thrombotic events, could have been revealed in early phases of drug development by using preclinical models of ischemia/reperfusion (I/R) injury. Rats that were treated with rofecoxib or vehicle for four weeks were subjected to 30 min. coronary artery occlusion and 120 min. reperfusion with or without cardioprotection that is induced by ischemic preconditioning (IPC). Rofecoxib increased overall the arrhythmias including ventricular fibrillation (VF) during I/R. The proarrhythmic effect of rofecoxib during I/R was not observed in the IPC group. Rofecoxib prolonged the action potential duration (APD) in isolated papillary muscles, which was not seen in the simulated IPC group. Interestingly, while showing hidden cardiotoxicity manifested as a proarrhythmic effect during I/R, rofecoxib decreased the infarct size and increased the survival of adult rat cardiac myocytes that were subjected to simulated I/R injury. This is the first demonstration that rofecoxib increased acute mortality due to its proarrhythmic effect via increased APD during I/R. Rofecoxib did not interfere with the cardiprotective effect of IPC; moreover, IPC was able to protect against rofecoxib-induced hidden cardiotoxicity. These results show that cardiac safety testing with simple preclinical models of I/R injury uncovers hidden cardiotoxicity of rofecoxib and might reveal the hidden cardiotoxicity of other drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
49. Natural and synthetic antioxidants targeting cardiac oxidative stress and redox signaling in cardiometabolic diseases.
- Author
-
Barteková, Monika, Adameová, Adriana, Görbe, Anikó, Ferenczyová, Kristína, Pecháňová, Oľga, Lazou, Antigone, Dhalla, Naranjan S., Ferdinandy, Péter, and Giricz, Zoltán
- Subjects
- *
HEART metabolism disorders , *OXIDATIVE stress , *MOLECULAR pathology , *UBIQUINONES , *ANTIOXIDANTS , *VITAMIN A - Abstract
Cardiometabolic diseases (CMDs) are metabolic diseases (e.g., obesity, diabetes, atherosclerosis, rare genetic metabolic diseases, etc.) associated with cardiac pathologies. Pathophysiology of most CMDs involves increased production of reactive oxygen species and impaired antioxidant defense systems, resulting in cardiac oxidative stress (OxS). To alleviate OxS, various antioxidants have been investigated in several diseases with conflicting results. Here we review the effect of CMDs on cardiac redox homeostasis, the role of OxS in cardiac pathologies, as well as experimental and clinical data on the therapeutic potential of natural antioxidants (including resveratrol, quercetin, curcumin, vitamins A, C, and E, coenzyme Q10, etc.), synthetic antioxidants (including N-acetylcysteine, SOD mimetics, mitoTEMPO, SkQ1, etc.), and promoters of antioxidant enzymes in CMDs. As no antioxidant indicated for the prevention and/or treatment of CMDs has reached the market despite the large number of preclinical and clinical studies, a sizeable translational gap is evident in this field. Thus, we also highlight potential underlying factors that may contribute to the failure of translation of antioxidant therapies in CMDs. [Display omitted] • Oxidative stress (OxS) contributes to cardiac dysfunction in cardiometabolic diseases (CMDs). • Natural and synthetic antioxidants were shown to attenuate cardiac OxS in CMDs in animal studies. • Efficacy of antioxidants are controversial in clinical studies in CMD patients evidencing a translational gap. • Preclinical and clinical methodologies need improving to be able to establish therapeutic potential of antioxidants in CMDs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
50. Systematic review and network analysis of microRNAs involved in cardioprotection against myocardial ischemia/reperfusion injury and infarction: Involvement of redox signalling.
- Author
-
Makkos, András, Ágg, Bence, Petrovich, Balázs, Varga, Zoltán V., Görbe, Anikó, and Ferdinandy, Péter
- Subjects
- *
MYOCARDIAL ischemia , *MYOCARDIAL reperfusion , *REPERFUSION injury , *MICRORNA , *DRUG target , *NON-coding RNA - Abstract
Although myocardial ischemia-reperfusion injury (I/R) and its pathological consequences are the leading cause of morbidity and mortality worldwide, cardioprotective therapeutics are still not on the market. Oxidative stress, a major contributing factor to myocardial I/R, changes transcription of coding and non-coding RNAs, alters post-transcriptional modulations, and regulate protein function. MicroRNA (miRNA) expression can be altered by oxidative stress and microRNAs may also regulate cytoprotective mechanisms and exert cardioprotection againts I/R. Transcriptomic analysis of I/R and oxidative stress-induced alterations followed by microRNA-mRNA target interaction network analysis may reveal microRNAs and their mRNA targets that may play a role in cardioprotection and serve as microRNA therapeutics or novel molecular targets for further drug development. Here we provide a summary of a systematic literature review and in silico molecular network analysis to reveal important cardioprotective microRNAs and their molecular targets that may provide cardioprotection via regulation of redox signalling. [Display omitted] • Oxidative stress, a major contributing factor to myocardial I/R injury, changes transcription of coding and non-coding RNAs. • microRNAs may regulate cytoprotective mechanisms and exert cardioprotection against I/R injury. • Analysis of I/R- and oxidative stress-induced alterations may reveal novel molecular targets for further drug development. • microRNA-mRNA target interaction network analysis may reveal miRNA therapeutics. • Systematic literature review and network analysis resulted cardioprotective microRNAs in association redox signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.